Cancer Clinical Trial
Official title:
A Prospective Phase I Clinical Trial of Carbon Ion Radiation Therapy for Locally Advanced, Unresectable Pancreatic Cancer
Verified date | April 2020 |
Source | Albert Einstein College of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase I trial to determine the maximum tolerated dose of carbon ion radiotherapy for the treatment of locally advanced, unresectable, pancreatic cancer.
Status | Completed |
Enrollment | 14 |
Est. completion date | July 9, 2019 |
Est. primary completion date | July 9, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
Inclusion Criteria: 1. Signed the informed consent form; 2. Age = 18; 3. Capable of following the protocol 4. Cytologically or histologically proven diagnosis of adenocarcinoma of the pancreas; 5. Unresectable adenocarcinoma of the pancreas by radiographic criteria according to the criteria of the NCCN Guidelines and based on post-chemotherapy imaging or due to medical contraindications to radical resection; 6. No evidence of distant metastases based on imaging evaluation; 7. Maximum tumor and positive lymph node diameter = 6 cm; 8. ECOG Performance Status 0-1; 9. Life expectancy = 12 weeks; 10. Adequate blood function: absolute neutrophil count (ANC) =1.5 x 109/L, platelet count =100 x 109/L, and hemoglobin =9 g/dL (use of transfusion to achieve said levels or greater is acceptable); 11. Adequate liver function: total bilirubin <1.5 x ULN, and AST and ALT <2.5 x ULN; 12. Adequate kidney function: serum creatinine =1.25 x ULN or calculated creatinine clearance rate =50mL/min and urine protein <2+.If the patient's baseline urine protein is at =2+, urine samples must be taken for 24 hours to verify that urine protein is =1g; 13. Laboratory studies within 14 days prior to registration demonstrating that the internationalization standard ratio (INR) =1.5 and prothrombin time (PPT) =1.5 x ULN. 14. Prior receipt of 2-4 cycles of Gemcitabine-based systemic chemotherapy. Exclusion Criteria: 1. Lack of pathologic confirmation of pancreatic malignancy prior to treatment initiation; 2. ECOG Performance Status >=2; 3. Poor liver, kidney and bone marrow function that do not meet the requirements for treatment; 4. Persistent grade = 2 toxicity due to previous cancer treatment; 5. Patient has previously received abdominal radiation therapy or abdominal radioactive seed implantation; 6. Those wearing a cardiac pacemaker or another type of metal prosthetic implant whose normal functions may suffer interference from high energy radiation or that could affect the radiation target area; 7. Where it is not possible to achieve the predetermined safety dose limit with the dose equivalent limit of the organ at risk such as the liver or digestive tract, etc.; 8. If the doctor determines that the heavy proton or carbon ion dosage radiotherapy will not bring any benefit to the patient; 9. Patients suffering from another illness or other factors that could affect the proton or carbon ion therapy; 10. Pregnant (verified by serum or urine ß-HCG test) or breastfeeding females; 11. Drug-abuse or alcohol dependency; 12. HIV positive, including those that have received antiretroviral therapy; replicative stage of chronic Hepatitis B virus; active stage of Hepatitis C; and active stage of syphilis; 13. HBV positive patients suffering from replicative stage of hepatitis virus, requiring antiretroviral therapy but cannot due to a concomitant disease; 14. Patients with a history of mental illness that may prevent their completion of treatment; 15. Patients with serious complications that could affect the course of treatment, including: - Unstable angina, congestive heart failure, or myocardial infarction requiring hospital admittance over the last 6 months; - Acute or systemic bacterial infection; - Chronic exacerbated obstructive pulmonary disease or other respiratory system disease requiring inpatient treatment; - Impaired liver function or impaired kidney function; - Patients suffering from immunosuppression; 16. Patients with contraindications to receiving radiotherapy, such as a serious connective tissue disease (eg: scleroderma) 17. Patients that are unable to understand the objective of the treatment/cannot sign the informed consent form; 18. Patients that lack civil capacity to act or whose civil capacity to act is limited. |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Proton and Heavy Ion Center | Shanghai | Shanghai |
United States | Albert Einstein College of Medicine | Bronx | New York |
Lead Sponsor | Collaborator |
---|---|
Albert Einstein College of Medicine | Shanghai Proton and Heavy Ion Center |
United States, China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose-limiting toxicity | Any CTCAE v. 4.03 non-hematologic adverse event of grade 3 or higher or any hematologic adverse event of grade 4 or higher, occurring within 90 days of the start of radiotherapy and deemed to be related to carbon ion radiotherapy. | 90 days | |
Secondary | Any grade 2 or higher treatment-related toxicity, scored using CTCAE v. 4.0 | Any grade 2 or higher treatment-related toxicity, scored using CTCAE v. 4.0 | through study completion, an average of 1 year | |
Secondary | Radiographic changes following completion of study therapy (RECIST v. 1.1) | Radiographic changes following completion of study therapy (RECIST v. 1.1) | through study completion, an average of 1 year | |
Secondary | Overall survival duration | The length of time from study inclusion until death from any cause | through study completion, an average of 1 year | |
Secondary | Progression-free survival duration | The length of time from study inclusion until death from any cause or disease progression at any site | through study completion, an average of 1 year | |
Secondary | The impact in terms of overall quality of life of radiation therapy as assessed by the QLQ-C30 questionnaire | Quality of life will be assessed at various time points using the European Organisation for Research and Treatment of Cancer 30 items dealing with fatigue, pain, nausea and vomiting, general condition and social, emotional and cognitive functions. It is currently used in many cancer related clinical trials. | through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|